KPTI
NASDAQ · Biotechnology
Karyopharm Therapeutics Inc
$6.26
+0.17 (+2.79%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 23.41M | 24.30M | 18.75M |
| Net Income | -4,725,651 | -4,467,152 | -3,864,497 |
| EPS | — | — | — |
| Profit Margin | -20.2% | -18.4% | -20.6% |
| Rev Growth | +9.9% | +18.6% | +24.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 38.84M | 49.27M | 39.84M |
| Total Equity | 75.91M | 65.47M | 76.64M |
| D/E Ratio | 0.51 | 0.75 | 0.52 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -4,842,921 | -5,147,496 | -4,398,523 |
| Free Cash Flow | -2,987,444 | -3,231,735 | -3,403,763 |